CCTx 001
Alternative Names: CCTx-001Latest Information Update: 27 Dec 2024
At a glance
- Originator Advesya
- Class Antineoplastics; CAR-T cell therapies
- Mechanism of Action Immunologic cytotoxicity; Interleukin-1 receptor accessory protein inhibitors; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Acute myeloid leukaemia
- Preclinical Myelodysplastic syndromes
Most Recent Events
- 27 Dec 2024 Phase-I/II clinical trials in Acute myeloid leukaemia in France (Parenteral) prior to December 2024 (Advesya pipeline, December 2024), (NCT06281847),
- 27 Dec 2024 Preclinical trials in Myelodysplastic syndromes in France (Parenteral) prior to December 2024 (Advesya pipeline, December 2024)
- 13 Jun 2024 Pharmacodynamics data from a preclinical trial in Acute myeloid leukemia presented at the 29th Congress of the European Haematology Association (EHA-2024)